Hutchmed secures priority review in China for ORPATHYS and TAGRISSO combination therapy
Hutchmed (China) Limited has achieved a significant milestone with the acceptance of its New Drug Application (NDA) by China’s National Medical Products Administration (NMPA) for ... Read More
HUTCHMED to sell non-core JV for $608m to focus on oncology
HUTCHMED (China) Limited has taken a bold step in streamlining its operations by divesting its 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited (SHPL) for ... Read More